Rhamnazin

SKU: orb1684263

Description

Rhamnazin (3',7-Dimethylquercetin) is an orally bioavailable small molecule that acts as a VEGFR2 kinase inhibitor. Its anti-angiogenic and anti-tumor properties are studied in leukemia research, with both in vitro cellular assays and in vivo animal models demonstrating its potential therapeutic effects.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 552-54-5
• MW: 330.29
• Purity: 98.82%
• Formula: C₁₇H₁₄O₇
• SMILES: O=C1C(O)=C(OC2=CC(OC)=CC(O)=C12)C=3C=CC(O)=C(OC)C3
• Target: VEGFR

Bioactivity

• Target IC50:
  VEGFR2:4.68 μM
• In Vivo:
  Treatment with Rhamnazin (10-30 mg/kg) significantly improved experimental brain injury in rats, with results showing significant reduction of edema and improved grip strength. Rhamnazin (200 mg/kg/ day orally) significantly inhibited the growth of human tumor xenografts and reduced the microvascular density (MVD) of tumor sections.
• In Vitro:
  Rhamnazin (5, 10, and 15 µM, 24h) reduces the proliferation and invasion of hepatocellular carcinoma (HCC) cells. Rhamnazin directly inhibited VEGFR2 kinase activity in a dose-dependent manner with an IC50 of 4.68 μM.

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

3',7-Dimethylquercetin, Rhamnazin

Compound Identifiers

PubChem CID

5320945